Did you know? You can suggest edits to improve this peptide information.
Overview
What is Bioglutide?
Bioglutide (NA-931) is a first-in-class oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors simultaneously. Developed by Biomed Industries, this small molecule derived from a cyclic IGF-1 fragment demonstrates remarkable oral bioavailability and blood-brain barrier penetration. Phase 2 clinical trials showed up to 13.8% body weight reduction in 13 weeks while preserving muscle mass - a significant advantage over existing GLP-1 therapies. Currently in Phase 2b/3 trials for obesity and type 2 diabetes.
Key Benefits
Oral administration (no injections), muscle-sparing weight loss, once-daily dosing with or without food, milder GI side effects than injectable GLP-1s, quadruple receptor activation for comprehensive metabolic effects.
Mechanism of Action
NA-931 is a small lipophilic molecule derived from cyclic IGF-1 fragment that crosses the blood-brain barrier. Simultaneously activates IGF-1 (muscle preservation, insulin sensitivity), GLP-1 (appetite suppression, insulin secretion), GIP (glucose metabolism, fat storage), and glucagon (energy expenditure, fat oxidation) receptors.
Molecular Information
Weight
Proprietary (small molecule)
Length
Small cyclic structure
Type
Cyclic IGF-1 fragment derivative
Amino Acid Sequence:
Proprietary - derived from cyclic glycine-proline analog of IGF-1
* Lipophilic small molecule optimized for oral bioavailability and BBB penetration
Pharmacokinetics
Research Indications
Obesity Management
Phase 2 showed 13.8% body weight reduction at 150mg daily in 13 weeks. 72% of subjects achieved ≥12% weight loss vs 2% placebo. Supports Phase 3 development.
Muscle Preservation
Unlike existing GLP-1 therapies, no muscle loss observed in clinical trials. IGF-1 receptor activation promotes protein synthesis while reducing fat mass.
Visceral Fat Reduction
Preclinical data showed 46% reduction in liver fat content. Targets metabolically harmful visceral adipose tissue.
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
NA-931 can be taken at any time of day with or without food. Unlike oral semaglutide, no fasting period or absorption enhancer required. Half-life of 16-24 hours supports once-daily dosing.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
NA-931 is administered as an oral capsule
Take once daily with a glass of water
Can be taken with or without food
Blood levels remain consistent regardless of fasting or fed state
No absorption enhancers required (unlike oral semaglutide)
Store at room temperature or refrigerated
Quality Indicators
Verified Research Source
Obtain from reputable research chemical suppliers with Certificate of Analysis (COA) and third-party testing.
Proper Packaging
Should be in sealed, moisture-protected container with batch number and purity information.
Consistent Appearance
Capsules or tablets should be uniform in size and color with no signs of degradation.
Limited Availability
NA-931 is an investigational compound - availability outside clinical trials is limited and unregulated.
Unknown Source
Never use compounds from unverified sources without analytical testing confirmation.
Discoloration or Moisture
Any color changes, moisture damage, or unusual odor indicates degradation.
What to Expect
- Week 1-2: Possible mild appetite reduction, minimal GI effects
- Week 2-4: Noticeable appetite suppression, early weight loss
- Week 4-8: Steady weight loss (1-2+ lbs/week), improved energy
- Week 8-13: Continued weight loss, 10-14% total reduction possible
- Side effects generally milder than injectable GLP-1 therapies
- Muscle mass preservation reported in clinical trials
- Metabolic improvements (glucose, lipids) develop over weeks
Side Effects & Safety
- Investigational drug - not yet FDA approved
- Start at lower dose (50mg) and titrate up as tolerated
- Most common side effects: mild nausea (7.3%), diarrhea (6.3-8.1%)
- 83% of GI adverse events rated mild or insignificant in trials
- No serious drug-related adverse events in Phase 2
- Caution with personal/family history of medullary thyroid carcinoma (GLP-1 class concern)
- Monitor for pancreatitis symptoms (severe abdominal pain)
- Drug interactions not fully characterized - avoid stacking with other GLP-1 agonists
References
Phase 2 Clinical Trial - Obesity (2024)
Randomized, double-blind, placebo-controlled Phase 2 trial (NCT06564753). NA-931 showed dose-dependent weight loss up to 13.8% at 150mg daily. 72% of treated subjects achieved ≥12% weight loss vs 2% placebo. No muscle loss observed, distinguishing from existing therapies.
View Study (opens in new tab) →Phase 1 Trial - Safety and PK (2024)
First-in-human study in overweight/obese subjects and T2DM patients. Demonstrated excellent safety profile with maximum 6.4% weight loss in 4 weeks. Blood levels consistent regardless of fasting or fed state. No serious adverse events reported.
View Study (opens in new tab) →EASD 2025 Presentation - Phase 2 Results
Presented at EASD Vienna 2025. Maximum body weight reduction of 14.8% (13.2% placebo-adjusted). 83% of GI adverse events were mild or insignificant. Treatment-emergent adverse events predominantly mild. Supports progression to Phase 3.
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia